Clinical Roundup Breast cancer drug boosts leukemia treatment, OHSU-led study finds January 09, 2026Vol.52 No.1
Conversation with The Cancer LetterFreePodcast Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSUBrian Druker returns to executive role as president of the new Knight Cancer Group August 14, 2025Vol.51 No.32By Paul Goldberg and Sara Willa Ernst
In Brief Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia May 02, 2025Vol.51 No.17
Conversation with The Cancer Letter Brian Druker steps down as CEO of OHSU Knight Cancer Center December 06, 2024Vol.50 No.45By Paul Goldberg
Drugs & Targets Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision November 01, 2024Vol.50 No.41
Conversation with The Cancer Letter OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center directorEight NCI-designated centers believe the top job is too big for one person April 05, 2024Vol.50 No.14By Paul Goldberg
In Brief Brian Druker named OHSU Knight CEO; Tom Sellers named cancer center director March 22, 2024Vol.50 No.12
In Brief Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight October 27, 2023Vol.49 No.40
In Brief Tom Sellers named lead research officer at OHSU Knight Cancer Institute February 17, 2023Vol.49 No.07
In Brief Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight February 17, 2023Vol.49 No.07
